Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has earned a consensus rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $46.25.
ENTA has been the topic of several recent analyst reports. Royal Bank of Canada reiterated a “buy” rating and issued a $54.00 price target on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, JMP Securities boosted their price target on Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th.
Enanta Pharmaceuticals (ENTA) traded down $0.21 during trading hours on Friday, hitting $48.19. The company had a trading volume of 93,155 shares, compared to its average volume of 193,710. Enanta Pharmaceuticals has a fifty-two week low of $25.92 and a fifty-two week high of $51.33. The firm has a market capitalization of $923.97, a PE ratio of 55.00 and a beta of 0.64.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million during the quarter, compared to analyst estimates of $73.80 million. During the same quarter last year, the firm posted ($0.09) EPS. The company’s revenue was up 491.3% compared to the same quarter last year. equities research analysts expect that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its holdings in Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after buying an additional 304 shares during the last quarter. Vanguard Group Inc. increased its holdings in Enanta Pharmaceuticals by 6.9% in the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock valued at $30,475,000 after buying an additional 54,856 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in Enanta Pharmaceuticals in the second quarter valued at about $205,000. Dimensional Fund Advisors LP increased its holdings in Enanta Pharmaceuticals by 34.3% in the second quarter. Dimensional Fund Advisors LP now owns 554,777 shares of the biotechnology company’s stock valued at $19,961,000 after buying an additional 141,688 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Enanta Pharmaceuticals by 43.0% in the second quarter. Goldman Sachs Group Inc. now owns 83,704 shares of the biotechnology company’s stock valued at $3,012,000 after buying an additional 25,154 shares during the last quarter. 66.97% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://ledgergazette.com/2017/12/12/enanta-pharmaceuticals-inc-enta-receives-46-25-average-target-price-from-analysts.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.